While Novo Nordisk already holds 27% of type-2-diabetes market share, data released over the weekend may help the company to further corner this market while providing a buffer against competition.

Objectives: The objective was to compare the use of low-dose liraglutide (LD-L) (Victoza) to the other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients without a type 2 diabetes (T2D) ...

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold under the brand names Victoza and Saxenda. Read on for everything you need ...

More > A 3-mg dose of Novo Nordisk's liraglutide (marketed as Victoza) showed significantly greater weight loss than placebo in a 56-week trial on obese patients with Type 2 diabetes. The company has ...

Keep up-to-date with everything that happens in your world.

LOS ANGELES (KABC) -- Many people taking a popular diabetes medication have been experiencing weight loss as one of the side effects. Low blood sugar levels brought 59-year-old Anda Lam to her ...

Ozempic shortages expected throughout 2024 Victoza shortages expected until at least Q2 2024 Diabetes drug Ozempic used 'off label' to treat obesity Nov 21 (Reuters) - Novo Nordisk (NOVOb.CO), opens ...

Eli Lilly is one step closer to launching its promising new diabetes drug dulaglutide--and one step closer to putting a crimp in Novo Nordisk's big-selling rival, Victoza. Lilly unveiled top-line ...

LONDON, April 23 (Reuters) - Novo Nordisk's new diabetes drug Victoza proved more effective than Merck & Co's Januvia in a head-to-head study, boosting prospects for a product that has got off to a ...

CINCINNATI (WKRC) - Some diabetes patients are facing a shortage. A drug they're supposed to take to fight their illness is also being used for weight loss. It's leaving those patients scrambling for ...

Branded content furnished by our promotional partners. The Daily Sundial editorial staff is not involved in its production. Content does not reflect the views or opinions of the editorial staff.